Northern Trust
PRLD icon

Northern Trust’s Prelude Therapeutics PRLD Stock Holding History

Northern Trust’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$171K Hold
50,120
– – ﹤0.01% 3986
2025
Q4 		$145K Buy
50,120
+13,699
+38% +$23.1K ﹤0.01% 4067
2025
Q3 		$52.4K Sell
36,421
-1,706
-4% -$1.71K ﹤0.01% 4280
2025
Q2 		$30.9K Sell
38,127
-78,780
-67% -$68.2K ﹤0.01% 4303
2025
Q1 		$89.8K Buy
116,907
+33,520
+40% +$31.3K ﹤0.01% 4141
2024
Q4 		$106K Sell
83,387
-22,990
-22% -$30.5K ﹤0.01% 4144
2024
Q3 		$220K Sell
106,377
-18,309
-15% -$84.8K ﹤0.01% 3855
2024
Q2 		$475K Buy
124,686
+2,539
+2% +$10.3K ﹤0.01% 3535
2024
Q1 		$579K Buy
122,147
+8,050
+7% +$31.3K ﹤0.01% 3516
2023
Q4 		$487K Sell
114,097
-1,421
-1% -$4.33K ﹤0.01% 3545
2023
Q3 		$357K Buy
115,518
+33,923
+42% +$127K ﹤0.01% 3611
2023
Q2 		$367K Buy
81,595
+60,428
+285% +$361K ﹤0.01% 3620
2023
Q1 		$121K Hold
21,167
– – ﹤0.01% 4035
2022
Q4 		$128K Hold
21,167
– – ﹤0.01% 4014
2022
Q3 		$140K Hold
21,167
– – ﹤0.01% 4010
2022
Q2 		$110K Sell
21,167
-80,739
-79% -$411K ﹤0.01% 4138
2022
Q1 		$703K Sell
101,906
-5,278
-5% -$48.3K ﹤0.01% 3597
2021
Q4 		$1.33M Buy
107,184
+759
+0.7% +$12.3K ﹤0.01% 3427
2021
Q3 		$3.33M Sell
106,425
-12,252
-10% -$397K ﹤0.01% 3001
2021
Q2 		$3.4M Buy
118,677
+3,178
+3% +$113K ﹤0.01% 3069
2021
Q1 		$5M Buy
115,499
+476
+0.4% +$31.6K ﹤0.01% 2737
2020
Q4 		$8.23M Buy
+115,023
New +$5.72M ﹤0.01% 2377

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Northern Trust's PRLD Position: Q1 2026 in Review

Northern Trust held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 50,120 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #3986.

Northern Trust first reported a position in PRLD in Q4 2020 and has held it in 22 quarters since. The position peaked at $8.23M in Q4 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Northern Trust held 50,120 shares of Prelude Therapeutics worth $171K as of Q1 2026.
  • Northern Trust left its Prelude Therapeutics share count unchanged in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3986 holding.
  • Northern Trust first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Northern Trust's Prelude Therapeutics position peaked at $8.23M in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.